CVS Health Eyes Margin Recovery and Cash Flow as 2027 Headwinds Loom

Improving Momentum Across Core Segments

CVS Health executives said the company is seeing improved execution across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on healthcare cost trends and several 2027 headwinds. Speaking at an investor conference, Chief Financial Officer Brian Newman said Aetna has been on a "steady march" toward target margins since 2024, pharmacy operations have returned to mid-single-digit growth after several years of declines, and Caremark is expected to meet its guidance for the year. He also cited progress at Oak Street Health and reduced leverage as contributors to the company's improving execution.

Newman said CVS Health is "getting to a place where we are happy and start to spin off cash," adding that the company is focused on building credibility by delivering on its stated plans. Leverage has been reduced to the mid-3-times range, pharmacy growth has returned to the mid-single digits, and management signaled it plans to support the dividend, potentially resume share buybacks in 2026, and consider disciplined bolt-on acquisitions.

Aetna Targets Margin Recovery Amid Medical Cost Pressure

Steve Nelson, president of Aetna, attributed the health insurer's improved performance to a stronger operating foundation, including forecasting, pricing discipline and Medicare Advantage bid management. He said 12 of Aetna's 13 senior executives are either new to their roles or new to Aetna over the last two years. Nelson said the company is also pursuing differentiation through prior-authorization reform, provider partnerships, consumer navigation and digital tools.

While Nelson acknowledged "pockets of favorability," particularly in Medicare Advantage, he said absolute healthcare costs remain elevated. Aetna has approximately 2,000 initiatives aimed at managing medical cost trends, including products intended to steer members toward high-quality providers, expanded care navigation and closer coordination with clinicians. Management is taking a cautious approach to 2027 Medicare Advantage bids and faces uncertainty around Medicaid policies.

2027 Headwinds and Capital Allocation Plans

Several 2027 risks remain, including declining 340B revenue, a less robust Caremark selling season and potentially changing health-plan enrollment. Management tied those items to the broader caution shaping its 2027 outlook and its willingness to wait for clearer signals before committing more capital. The company plans to support its dividend, potentially resume share buybacks in 2026, and consider disciplined bolt-on acquisitions as cash generation improves.

Near-Term Investor Signals

The conference remarks mark the next verifiable communication from CVS Health management following its prior quarterly earnings call, with investors watching for further updates on Medicare Advantage bid outcomes, Caremark selling-season results, and any resumption of share buybacks in 2026.